Estradiol Patches
ID: SPE2D217R0016Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/673d600572e4499b836b206c6112849a/view
Timeline
    Description

    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking Estradiol Patches. Estradiol Patches are typically used for hormone replacement therapy in women to alleviate symptoms of menopause such as hot flashes, vaginal dryness, and mood swings. The place of performance for this procurement is DLA Troop Support, 700 Robbins Avenue, Philadelphia, PA 19111, USA. For more information, please contact Catherine Gilbert at catherine.gilbert@dla.mil or 215-737-4778.

    Lifecycle
    Title
    Type
    Estradiol Patches
    Currently viewing
    Presolicitation
    Similar Opportunities
    ESTRADIOL TABLETS
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is seeking ESTRADIOL TABLETS. ESTRADIOL TABLETS are typically used for hormone replacement therapy and the treatment of menopause symptoms.
    Norgestimate/Ethinyl Estradiol Tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a presolicitation for a national requirements contract for Norgestimate/Ethinyl Estradiol Tablets. The procurement will include various formulations of these oral tablets, specifically Norgestimate Ethinyl Estradiol Triphasic Low Dose Oral Tablets and Ethinyl Estradiol/Norgestimate tablets, packaged in 3x28 count packs. This contract is crucial for establishing a national supply source for the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons, ensuring a reliable provision of these essential pharmaceuticals. Interested parties should prepare for the solicitation, projected for November 2024, and may contact Kyle Lewicki at (215) 737-3696 or kyle.lewicki@dla.mil for further inquiries.
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is modifying contract SPE2D220D0090 to correct an administrative error for the procurement of Norgestimate/Ethinyl Estradiol Oral Tablets. Norgestimate/Ethinyl Estradiol Oral Tablets are typically used for contraception and hormone replacement therapy.
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking Norgestimate/Ethinyl Estradiol Oral Tablets. These tablets are typically used for oral contraception.
    Tolterodine Tartrate ER
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is seeking Tolterodine Tartrate ER. Tolterodine Tartrate ER is a drug used for the treatment of overactive bladder. The procurement will be fulfilled by DLA Troop Support in Philadelphia, PA, USA. For more information, contact Catherine Gilbert at catherine.gilbert@dla.mil or 2157374778.
    Duloxetine HCL DR
    Active
    Dept Of Defense
    Presolicitation notice for Duloxetine HCL DR. The service/item being procured is typically used for medical, dental, and veterinary equipment and supplies. The place of performance is in Philadelphia, PA, USA at DLA Troop Support, 700 Robbins Avenue, 19111. The primary contact for this procurement is Joan Grace, who can be reached at JoanMarie.Grace@dla.mil or 215-737-2663.
    Pramipexole Tablets
    Active
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for Pramipexole Tablets under solicitation number SPE2D2-24-R-0017. This procurement aims to acquire pharmaceutical products, specifically Pramipexole in various dosages, to support military health needs. The solicitation outlines detailed requirements for offerors, including submission instructions via the Defense Logistics Agency Internet Bid Board System (DIBBS), compliance with federal regulations, and the necessity for performance assessments and ethical conduct. Interested contractors should reach out to Ryan Guarnere at Ryan.Guarnere@dla.mil or Jason Wray at jason.wray@dla.mil for further information regarding the submission process and compliance requirements.
    Bicalutamide 50MG tablets
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health programs. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base period and four one-year options, with the solicitation expected to be posted on the DLA Bid Board System and Sam.gov. Interested parties should direct inquiries to Keith Ryales at keith.ryales@dla.mil or call 215-737-9199 for further information.
    CLOBETASOL PROPIONATE 0.05% SOLUTION
    Active
    Dept Of Defense
    Presolicitation Department of Defense is seeking CLOBETASOL PROPIONATE 0.05% SOLUTION. This item falls under the category of MEDICAL/DENTAL/VETERINARY EQPT/SUPP and has a PSC code of 65. For more information, please contact Denise Taubman at denise.taubman@dla.mil or 215-737-8677.
    Lamotrigine
    Active
    Dept Of Defense
    The Defense Logistics Agency (DLA) is preparing to issue a solicitation for a national requirements contract for Lamotrigine ER Tablets, specifically in dosages of 25MG, 50MG, 100MG, 200MG, 250MG, and 300MG, packaged in 30 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are critical for various Department of Defense and other federal health service customers, including the Bureau of Prisons and the Department of Veterans Affairs. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, and it is expected to be fully competitive and unrestricted. Interested parties should prepare for the solicitation, projected for November 2024, and can direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or by phone at 215-737-4955.